TREATMENT STRATEGIES FOR SARCOIDOSIS

被引:1
作者
Viaene, E. [1 ]
Thomeer, M. [1 ]
Slabbynck, H. [1 ]
Wuyts, W. [1 ]
机构
[1] UZ Leuven, Dept Pneumol, Unit Interstitial Lung Dis, Louvain, Belgium
关键词
sarcoidosis; treatment; anti-TNF; TUMOR-NECROSIS-FACTOR; PULMONARY SARCOIDOSIS; DOUBLE-BLIND; STAGE-II; CORTICOSTEROID-THERAPY; REFRACTORY SARCOIDOSIS; RESISTANT SARCOIDOSIS; FACTOR INHIBITION; CONTROLLED-TRIAL; INFLIXIMAB;
D O I
10.2143/ACB.67.2.2062636
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Sarcoidosis is a multisystem disorder of unknown cause with a highly variable course. Corticosteroids are considered the standard agent for treatment, however there is no consensus about when and in whom therapy should be initiated, what dose should be given and for how long. There seems to be a limited benefit on chest radiographic findings, forced vital capacity and diffusing capacity. The evidence supporting the disease-modulating effect is limited. Cytotoxic agents are often used as steroid-sparing in patients requiring chronic therapy, however there are only little randomized controlled trials to support their use and side effects are common. Tumour necrosis factor-a is thought to be crucial in the development of the typical granulomas in sarcoidosis. Many case reports and case series suggest that specific therapy targeted against this cytokine is very effective. Despite these promising results, only limited evidence is found in multicenter randomized controlled trials.
引用
收藏
页码:83 / 87
页数:5
相关论文
共 48 条
[1]  
[Anonymous], 1999, Am J Respir Crit Care Med, V160, P736
[2]  
Baughman R., 2005, Eur Respir Mon, V32, P301
[3]   Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement [J].
Baughman, Robert P. ;
Drent, Marjolein ;
Kavuru, Mani ;
Judson, Marc A. ;
Costabel, Ulrich ;
du Bois, Roland ;
Albera, Carlo ;
Brutsche, Martin ;
Davis, Gerald ;
Donohue, James F. ;
Mueller-Quernheim, Joachim ;
Schlenker-Herceg, Rozsa ;
Flavin, Susan ;
Lo, Kim Hung ;
Oemar, Barry ;
Barnathan, Elliot S. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 174 (07) :795-802
[4]  
Baughman RP, 2005, CHEST, V128, P1062, DOI 10.1378/chest.128.2.1062
[5]  
Baughman RP, 2000, SARCOIDOSIS VASC DIF, V17, P60
[6]   New treatment for sarcoidosis: where's the proof? [J].
Baughman, RP ;
Lower, EE .
EUROPEAN RESPIRATORY JOURNAL, 1999, 14 (05) :1000-1001
[7]   Thalidomide for chronic sarcoidosis [J].
Baughman, RP ;
Judson, MA ;
Teirstein, AS ;
Moller, DR ;
Lower, EE .
CHEST, 2002, 122 (01) :227-232
[8]  
Baughman RP, 2001, SARCOIDOSIS VASC DIF, V18, P310
[9]   Sarcoidosis [J].
Baughman, RP ;
Lower, EE ;
du Bois, RM .
LANCET, 2003, 361 (9363) :1111-1118
[10]   Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials [J].
Bongartz, T. ;
Warren, F. C. ;
Mines, D. ;
Matteson, E. L. ;
Abrams, K. R. ;
Sutton, A. J. .
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (07) :1177-1183